Arginine silicate inositol for improving cognitive function

Abstract

The present disclosure relates to the use of inositol-stabilized arginine (“ASI”) for improving cognition. For example, in some implementations, methods include administering an amount of ASI effective to improve cognition in humans. Some embodiments include the use of ASI for improving mental focus and/or attention span. For example, in some implementations, methods include administering an amount of ASI effective to improve mental focus and/or attention span in humans. Some embodiments include the use of ASI for treating and/or preventing cognitive disorders. Cognitive disorders may include stroke, anoxic brain injury, traumatic brain injury, dementia, Alzheimer's disease, Parkinson's disease, MCI, and age-related memory loss, attention deficit hyperactivity disorder (“ADHD”), and other learning disabilities.

What is claimed is: 
     
         1 . A method of improving cognitive functioning in a human comprising:
 identifying a human in need of improved cognitive functioning; and   administering an amount of inositol-stabilized arginine silicate effective to improve cognitive functioning in the human.   
     
     
         2 . The method of  claim 1 , wherein identifying includes identifying a mentally fatigued human. 
     
     
         3 . The method of  claim 1 , wherein identifying includes identifying a physically fatigued human. 
     
     
         4 . The method of  claim 1 , wherein identifying includes administering one or more cognitive tests 
     
     
         5 . The method of  claim 1 , wherein identifying includes a diagnosis of ADHD. 
     
     
         6 . The method of  claim 1 , wherein the amount of inositol-stabilized arginine silicate administered is between about 0.5 g to 5 g per day. 
     
     
         7 . The method of  claim 1 , wherein the amount of inositol-stabilized arginine silicate administered is about 1,500 mg per day. 
     
     
         8 . The method of  claim 1 , wherein the administering includes self-administering a composition by mouth, the composition having an amount of inositol-stabilized arginine silicate that is about 1,500 mg. 
     
     
         9 . The method of  claim 1 , further comprising administering an amount of a chromium containing complex. 
     
     
         10 . A method of improving cognitive function comprising:
 identifying a cognitive disorder in a subject; and   administering a therapeutically effective amount of inositol-stabilized arginine silicate to the subject.   
     
     
         11 . The method of  claim 10 , wherein the identifying includes administering a test that is sensitive to detecting one or more cognitive disorders. 
     
     
         12 . The method of  claim 11 , wherein the test is sensitive to detecting a disease or disorder selected from the group consisting of one or more of stroke, anoxic brain injury, traumatic brain injury, dementia, Alzheimer's disease, Parkinson's disease, MCI, and age-related memory loss. 
     
     
         13 . The method of  claim 10 , wherein identifying includes a diagnosis of ADHD. 
     
     
         14 . The method of  claim 10 , wherein the identifying includes identifying one or more genetic defects in the subject. 
     
     
         15 . The method of  claim 10 , wherein the administering comprises orally administering a composition containing a therapeutically effective amount of inositol-stabilized arginine silicate. 
     
     
         16 . The method of  claim 10 , wherein the therapeutically effective amount is between about 0.5 gram per day to 5 grams per day. 
     
     
         17 . A method for improving cognitive function comprising:
 administering a first cognitive evaluation to a subject;   determining the presence of a cognitive disorder in said subject;   administering a therapeutically effective amount of inositol-stabilized arginine silicate; and   administering a second cognitive evaluation on said subject,   wherein said second cognitive evaluation is improved relative to said first cognitive evaluation.   
     
     
         18 . The method of  claim 17 , wherein determining the presence of a cognitive deficit comprises determining whether the subject has a condition selected from stroke, anoxic brain injury, traumatic brain injury, dementia, Alzheimer's disease, Parkinson's disease, MCI, and age-related memory loss, or a combination of the foregoing. 
     
     
         19 . The method of  claim 18 , wherein the first and second cognitive evaluations are independently selected from the Automatic Trail making Test A; the Automatic Trail making Test B; Profile of Mood States; Modified Mini-Mental State Examination; Three Word Recall; 7-Minute Screen; AB Cognitive Screen; Addenbrooke's Cognitive Examination (Revised); Abbreviated Mental Test; Brief Alzheimer Screen; Brief Cognitive Scale; Cognitive Abilities Screening Instrument; Cognitive Assessment Screening Test; Cognitive Capacity Screening Examination; Clock Drawing Test; DemTect; Dementia Questionnaire; General Practitioner Assessment of Cognition; Hopkins Verbal Learning Test; Informant Questionnaire on Cognitive Decline in the Elderly; Informant Questionnaire on Cognitive Decline in the Elderly—Short Form; Minnesota Cognitive Acuity Screen; Mini-Cog; Memory Impairment Screen; Mini-Mental State Examination; Mont Montpellier Screen; Neurobehavioral Cognitive Status Examination; Rotterdam Version of the Cambridge Cognitive Examination; Rapid Dementia Screening Test; Short and Sweet Screening Instrument; Symptoms of Dementia Screener; Six Item Screener; Short Memory Questionnaire; Short Orientation Memory Concentration Test; Short Portable Mental Status Questionnaire; Short Test of Mental State; Time and Change; Telephone Interview of Cognitive Status-Modified; Verbal Fluency; Modified WORLD Test, or a combination of the foregoing. 
     
     
         20 . The method of  claim 17 , wherein the therapeutically effective amount is between about 0.5 gram per day to about 5 grams per day.